Czech Republic-based Sotio Biotech announced that it has entered into a clinical trial collaboration and supply agreement with Merck & Co. (MSD) to evaluate the combination of Sotio's lead superagonist (SOT101) and Merck's Keytruda in a phase 2 solid tumor study.
Under the terms of the deal, Sotio will conduct the phase 2 open-label, multicenter study of SOT101 in combination with Keytruda to evaluate efficacy and safety in patients with selected advanced or refractory solid tumors. The study will enroll patients in the U.S. and selected European countries across six different indications, including second line non-small cell lung cancer, first and second line cutaneous squamous cell carcinoma, first line microsatellite instability-high colorectal cancer, second line hepatocellular carcinoma, first line metastatic castration-resistant prostate cancer and second line ovarian cancer.
Sotio is also testing SOT101 as a monotherapy, evaluating its use in patients with melanoma, squamous skin carcinoma and kidney cancer.
